Objective: To study the usefulness of combined detection of 4 tumor markers in patients with recrudescent and metastatic breast cancer.
Methods: The serum levels of CA153, CEA, TPS and CA125 were determined by chemiluminescence immunoassay. A total of 1245 subjects entered the study. Sensitivities of the tests were evaluated in 1 000 patients with breast cancer (102 preoperative patients and 898 postoperative patients) and 245 with benign breast disease.
Results: The serum levels of CA153, CEA and TPS were significantly elevated in preoperative patients compared with metastatic patients (P<0.001). The serum levels of CA153, CEA, TPS and CA125 were significantly elevated in metastatic patients compared with non-metastatic patients (P<0.001). The sensitivity of the 4 tumor markers were significantly elevated in metastatic patients compared with preoperative and postoperative non-metastatic patients (P<0.05). The sensitivity of combined detection of the 4 tumor markers were 56.72% and 94.68% in preoperative patients and metastatic patients, respectively. The CEA elevation was strongly correlated with CA153 and TPS levels (all P=0.000 1, r=0.410 and 0.396, respectively).
Conclusion: Combined detection of the 4 tumor markers may play a guiding role in post-therapeutic monitoring of breast cancer in progressive, recrudescent and metastatic patients.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment